Clinical Research Directory

Inclusion Criteria: * Participants must be women who have histological confirmation of HER2 positive breast cancer * The primary tumor must be \>= 2.0cm in size and/or have biopsy proven axillary nodes that are \>= 2.0cm in size by mammography, ultrasound, or magnetic resonance imaging (MRI) * The current cancer must over express HER2 as determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) * Patients may not have received prior HER2 directed therapies * Participants must have normal cardiac ejection fraction (per label, as defined as institutional normal) * Planned neoadjuvant therapy with six cycles of combined pertuzumab, trastuzumab and chemotherapy * Ability to provide informed consent * Negative Serum Pregnancy test Exclusion Criteria: * Participants who are not considered candidates for pertuzumab + trastuzumab + chemotherapy * Concurrent malignancy other than non-melanoma skin cancer * Patients must not have known metastatic disease * Patients must not have received prior treatment for the current breast cancer